A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Natalie YL Ngoi; Valerie Heong; Samuel Ow; Wen Yee Chay; Hee Seung Kim; Chel Hun Choi; Geraldine Goss; Jeffrey C Goh; Bee Choo Tai; Diana GZ Lim; Nivashini Kaliaperumal; Veonice B Au; John E Connolly; Jae-Weon Kim; Michael Friedlander; Kidong Kim; David SP Tan

doi:10.1136/ijgc-2020-001604

Citation Tools

other Versions

You are currently viewing an earlier version of this article (February 08, 2021).
View the most recent version of this article

PDF

Clinical trial

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Ngoi NY, Heong V, Ow S, et al

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

International Journal of Gynecologic Cancer Published Online First: 25 June 2020. doi: 10.1136/ijgc-2020-001604

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password